ArticlePloS one2010
Strand transfer and elongation of HIV-1 reverse transcription is facilitated by cell factors in vitro.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Mechanism of HIV-1 Capsid Rupture and Uncoating by Reverse Transcription.bioRxiv : the preprint server for biology · 2026Article
- The HIV-1 capsid and reverse transcription.Retrovirology · 2021Review
- Oxazole-Benzenesulfonamide Derivatives Inhibit HIV-1 Reverse Transcriptase Interaction with Cellular eEF1A and Reduce Viral Replication.Journal of virology · 2019Article
- PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating.Journal of virology · 2018Article
- Template-primer binding affinity and RNase H cleavage specificity contribute to the strand transfer efficiency of HIV-1 reverse transcriptase.The Journal of biological chemistry · 2018Article
- Article
- HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis.Nature · 2016Article
- Specific Interaction between eEF1A and HIV RT Is Critical for HIV-1 Reverse Transcription and a Potential Anti-HIV Target.PLoS pathogens · 2015Article
- A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.Journal of virology · 2015Article
- Tetraspanin CD63 is a regulator of HIV-1 replication.International journal of clinical and experimental pathology · 2015Article
- Impairment of HIV-1 cDNA synthesis by DBR1 knockdown.Journal of virology · 2014Article
- HIV-1-associated PKA acts as a cofactor for genome reverse transcription.Retrovirology · 2013Article
- Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate.Small (Weinheim an der Bergstrasse, Germany) · 2013Article
- Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay.Retrovirology · 2013Article
- The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis.Microbiology and molecular biology reviews : MMBR · 2013Review
- Inhibition of reverse transcriptase activity increases stability of the HIV-1 core.Journal of virology · 2013Article
- Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- A post-entry role for CD63 in early HIV-1 replication.Virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent work suggests a role for multiple host factors in facilitating HIV-1 reverse transcription. Previously, we identified a cellular activity which increases the efficiency of HIV-1 reverse transcription in vitro. Here, we describe aspects of the activity which shed light on its function. The cellular factor did not affect synthesis of strong-stop DNA but did improve downstream DNA synthesis. The stimulatory activity was isolated by gel filtration in a single fraction of the exclusion volume. Velocity-gradient purified HIV-1, which was free of detectable RNase activity, showed poor reverse transcription efficiency but was strongly stimulated by partially purified cell proteins. Hence, the cell factor(s) did not inactivate an RNase activity that might degrade the viral genomic RNA and block completion of reverse transcription. Instead, the cell factor(s) enhanced first strand transfer and synthesis of late reverse transcription suggesting it stabilized the reverse transcription complex. The factor did not affect lysis of HIV-1 by Triton X-100 in the endogenous reverse transcription (ERT) system, and ERT reactions with HIV-1 containing capsid mutations, which varied the biochemical stability of viral core structures and impeded reverse transcription in cells, showed no difference in the ability to be stimulated by the cell factor(s) suggesting a lack of involvement of the capsid in the in vitro assay. In addition, reverse transcription products were found to be resistant to exogenous DNase I activity when the active fraction was present in the ERT assay. These results indicate that the cell factor(s) may improve reverse transcription by facilitating DNA strand transfer and DNA synthesis. It also had a protective function for the reverse transcription products, but it is unclear if this is related to improved DNA synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.